

Impact on visual acuity and psychological outcomes of ranibizumab and subsequent treatment for diabetic macular oedema in Japan (MERCURY)

Taiji Sakamoto, Masahiko Shimura, Shigehiko Kitano, Masahito Ohji, Yuichiro Ogura, Hidetoshi Yamashita, Makoto Suzaki, Kimie Mori, Yohei Ohashi, Poh Sin Yap, Takeumi Kaneko, Tatsuro Ishibashi, for the MERCURY Study Group

Corresponding author:

Taiji Sakamoto

Department of Ophthalmology, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan

Tel: +81 99-275-5402

Fax: +81 99-265-4894

Email: tsakamot@m3.kufm.kagoshima-u.ac.jp

Online Resource 7. BCVA outcomes at month 12 (PTE set)

	PTE
Change, <i>n</i> (%)	(<i>N</i> = 209)
Change in BCVA (logMAR) from baseline to month 12, <i>n</i>	125
≤−0.1 (improved)	57 (45.6)
≤−0.2 (improved)	25 (20.0)
≤−0.3 (improved)	16 (12.8)
<0.3 (stable or improved)	117 (93.6)
≥0.3 (deteriorated)	8 (6.4)

BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; PTE, primary treated eye.